Abstract:2654 Background: Immune checkpoint inhibitors are revolutionizing cancer care and providing new treatment options with promising outcomes for many cancers. However, immune-related adverse events (irAEs) are not infrequent and can be severe. An intriguing relationship between the presence of irAEs and treatment efficacy has been described but lacks thorough characterization. We aimed to further elucidate a relationship between immune checkpoint inhibitor (ICI) irAEs and efficacy. Methods: We identified cancer patients treated with ICI from 2015-2021 across two institutions: Michael E DeBakey Veterans Affairs Medical Center (MEDVAMC) and Baylor St. Luke’s Medical Center (BSLMC). Clinical data including cancer type, irAEs type and grade, ICI response, progression free survival (PFS) and overall survival (OS) was collected. Using the Kaplan Meier method, survival curves were generated and comparisons were made amongst groups using the log-rank test. Fisher’s exact test was used to compare progression of disease between groups. To determine if variables were associated with survival, multivariable Cox regression analysis was used. Results: Of the 456 patients treated with ICI, irAEs were seen in 165 (36%) patients. Of these, 81 (49%) patients had grade 1 toxicities, most commonly arthritis, diarrhea, and dermatitis. 47 (28%) patients had grade 2 toxicities (colitis, hypothyroidism, adrenal insufficiency). 34 (21%) patients had grade 3 toxicities (pneumonitis, pancreatitis, hepatitis). 3 patients had grade 4 toxicities (pneumonitis, DRESS syndrome, and hepatorenal syndrome). 1 patient expired and 24 (15%) patients discontinued ICI due to irAEs. 55 (33%) of patients with irAEs were treated with steroids. For patients assessed for efficacy, objective response rate (ORR) to ICI was higher in patients with irAEs [47% (12% CR) vs 33% (11% CR)]. In fact, the presence of any irAEs was significantly likely to predict response to ICI (OR 1.90, 95% CI 1.25 - 2.86, p = 0.0026). In a subset of patients evaluable for survival (n = 375), patients with any irAEs had a significantly improved median PFS compared to those without irAEs (9.0 vs. 4.8 months, p = 0.0018). Multivariable analysis demonstrated that the development of any irAEs was related to a significantly improved OS (HR 0.63, 95% CI 0.43-0.89, p = 0.01). Conclusions: The development of irAEs in cancer patients treated with immunotherapy may predict better treatment efficacy and overall survival. Further prospective studies are needed to confirm these associations and mechanism of action.

Immune-Related Adverse Events in Patients on Immunotherapy Presenting to the Emergency Department: A Retrospective Cohort Study

Management and outcome of oncological patients under immune checkpoint inhibitors presenting at the emergency department

Immune-related adverse effects: Recognition and initiation of appropriate treatment in cancer patients on immunotherapy

Immune-related adverse events and immunotherapy efficacy in patients with cancer: A retrospective study.

Incidence of Immune-Related Adverse Events and Its Association with Treatment Outcomes: the MD Anderson Cancer Center Experience

Facts and Hopes in Prediction, Diagnosis, and Treatment of Immune-Related Adverse Events

Immune-mediated adverse event management at a tertiary care cancer center.

Evaluation of emergency department visits and immune-related adverse effects (irAEs) in patients treated with nivolumab

Immune-Related Adverse Events Due to Cancer Immunotherapy: Immune Mechanisms and Clinical Manifestations

Managing Select Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitors

Clinical assessment of immune-related adverse events

The Most Recent Oncologic Emergency: What Emergency Physicians Need to Know About the Potential Complications of Immune Checkpoint Inhibitors

Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signatures

Management of immune-related adverse events associated with immune checkpoint inhibitors in cancer patients: a patient-centred approach

Cardiovascular Events as Oncologic Emergencies in Patients on Immune- Checkpoint Inhibitor Therapy

Advances in Knowledge and Management of Immune-Related Adverse Events in Cancer Immunotherapy

Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentations

Acknowledging and addressing real-world challenges to treating immune-related adverse events

Commentary to: Cancer and treatment specific incidence rates of immune related adverse events induced by immune checkpoint inhibitors: a systematic review

Management of Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: A Minireview of Current Clinical Guidelines

[The pathology of adverse events with immune checkpoint inhibitors]